United Kingdom· GB-APID-32906211000001102
Bevacizumab 1% eye drops
A bevacizumab product containing bevacizumab, registered in United Kingdom by Special Order. The same ATC class is registered in 9 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Bevacizumab is registered in 9 of 19 countries.
Countries holding a registration under ATC S01LA08 (bevacizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 5 of them publish a price we can compare per daily dose
Bevacizumab · ATC S01LA08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Bevacizumab
- Manufacturer
- Special Order
- Country
- United Kingdom (GB)
- ATC code
- S01LA08
- ATC class
- Bevacizumab
- Defined daily dose
- 0.036 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5055227300773
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bevacizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesALYMSYSAmneal Pharmaceuticals LLC
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- BelgiumAbevmy 25 mg/mlBiosimilar Collaborations Ireland
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- SwitzerlandAbevmy
- SpainABEVMY 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBiosimilar Collaborations Ireland Limited
- CanadaABEVMYBIOSIMILAR COLLABORATIONS IRELAND LIMITED
- PolandAbevmyBiosimilar Collaborations Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3a75b0a-5981-48bb-894b-90d11be284e5 GET /v1/drugs/b3a75b0a-5981-48bb-894b-90d11be284e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "32906211000001102",
"desc": "Bevacizumab 1% eye drops (Special Order)",
"form": "Eye drops",
"vpid": "32906011000001107",
"source": "dmd",
"vtm_id": "774850001",
"strength": "10 mg",
"substance": "Bevacizumab",
"ingredient": "Bevacizumab",
"supplier_code": "8286711000001104"
}See everything about bevacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.